La cadena de opciones muestra datos clave de las opciones de acciones de Klotho Neurosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Klotho Neurosciences..

Klotho Neurosciences (NASDAQ:KLTO) Bolsa, Cadena de Opciones

Klotho Neurosciences

Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.

Stuttgart,,Germany,-,01-30-2025:,Mobile,Phone,With,Logo,Of,American

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AOUT

BRIA

BRZE

CDTG

CERO

CPRT

DOCU

FBIO

HOUR

ISPC

KLTO

LFVN

LULU

NVVE

Next Technology Holding Inc. - Ordinary Shares

NXTT

PXLW

SCAG

DocuSign sorprendió al mercado con resultados mejores de lo previsto y previsiones al alza, impulsando sus acciones antes de la apertura.

Acciones de DocuSign están cotizando un 8% más alto; Aquí están 20 acciones que se mueven en premercado

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences Inc

Press Releases

Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules

Contracts

Small Cap

Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology

Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market

Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar

Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership

Klotho Neurosciences Announces Expiration of Letter of Intent

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

AlphaTON Capital

Boundless Bio

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

iBio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Lunai Bioworks

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Nanoviricides

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

NextCure

Pluri

Q32 Bio

Rallybio

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tenax Therapeutics

Tharimmune

Exicure

Comments

Klotho Neurosciences

Klotho Neurosciences (KLTO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL